Concurrent antiphospholipid syndrome and sutaneous sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C

Journal of Drugs in Dermatology

Volumn 8, Issue 9, 2009, Pages 870-872

  Shinohara, Michi M ^a   Davis, Claudia ^a   Olerud, John ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 8; LOW MOLECULAR WEIGHT HEPARIN; PEGINTERFERON ALPHA; RIBAVIRIN; WARFARIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; DISEASE COURSE; DOPPLER ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; HEPATITIS C; HUMAN; HYPERPIGMENTATION; LEUKOCYTOCLASTIC VASCULITIS; LIVEDO RETICULARIS; RECURRENT DISEASE; SARCOIDOSIS; SKIN BIOPSY; THORAX RADIOGRAPHY; THROMBOPHLEBITIS; THROMBOSIS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; MIDDLE AGED;

ANTIPHOSPHOLIPID SYNDROME; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; SARCOIDOSIS;

EID: 70349322573     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Armstrong GL, Wesley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
2. Deufic-Burban S, Poynard T, Sulkowski MS, et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepatitis. 2007;14(2):107-115. (Pubitemid 46146705)
3. Wise M, Bialek S, Finelli L, Bell BP, et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008;47(4):1128-1135.
4. Zignego AL, Ferri C, Pileri SA, et al. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig and Liver Dis. 2007;39(1):2-17. (Pubitemid 46039435)
5. Abdallah MA, Ghozzi MY, Monib HA, et al. Necrolytic acral erythema: A cutaneous sign of hepatitis C virus infection. J Am Acad Dermatol. 2005;53(2):247-251. (Pubitemid 40979580)
6. Ramos-Casals M, Mana J, Nardi N, et al. Sarcoidosis in patients with chronic hepatitis C virus infection. Medicine. 2005;84(2):69-80. (Pubitemid 40418635)
7. Amin NM. Antiphospholipid syndromes in infectious diseases. Hematol Oncol Clin N Am. 2008;22(1):131-143.
8. Galossi A, Guarisco R, Bellis L, et al. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis. 2007;1(1)6:65-73. (Pubitemid 46548592)
9. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J of Hepatol. 2004;40(2):341-352. (Pubitemid 38115844)
10. Ordi-Ros J, Villarreal J, Monegal F, et al. Anticardiolipin antibodies in patients with chronic Hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diagn Lab Immunol. 2000;7(2):241-244. (Pubitemid 30132118)
11. Sthoeger ZM, Fogel M, Smirov A, et al. Anticardiolipin autoantibodies in serum samples and cryoglobulins of patients with chronic hepatitis C infection. Ann Rheum Dis. 2000;59(6):483-486. (Pubitemid 30395607)
12. Yasuda S, Atsumi T, Ieko M, et al. Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis. Thromb Res. 2004;114(5-6):461-465.
13. Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus. 2008;17:888-894.
14. Fried MW, Shiffman ML, Reddy J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
15. Hauschild A, Kahler KC, Shafer M, et al. Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol Ges. 2008;6:829-838.
16. Gogas H, Ioannovich J, Dafni U, et al. Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. N Engl J Med. 2006;354(7):709-718. (Pubitemid 43247141)
17. Okanouea T, Sakamotoa S, Itoha Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J of Hepatol. 1996;25(3):283-291.
18. Carmona-Soria I, Jimenez-Saenz J, Gonzalez-Vilches J, et al. Development of lupus anticoagulant during combination therapy in a patient with chronic hepatitis C. J of Hepatol. 2001;34:965-967. (Pubitemid 32595204)
19. Balderramo DC, Garcia O, Colmenero J et al. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. Dig Liver Dis. 2008; doi:10.1016.j.dld.2007.11.029.
20. Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C. Arch Dermatol. 2005;141:865-868. (Pubitemid 41058068)
21. Perera GK, Calonje E. Systemic sarcoidosis presenting in a tattooed man undergoing treatment for hepatitis C. Clin and Exp Derm. 2006;31:387-389.
22. Doyle MK, Berggren R, Magnus JH. Interferon-induced sarcoidosis. J Clin Rheumatol. 2006;12:241-248. (Pubitemid 44527044)